Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?

MeSH terms

• Adenocarcinoma / therapy*
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Carcinoma, Pancreatic Ductal / therapy*
• Female
• Humans
• Male
• Neoplasm Recurrence, Local / therapy*
• Pancreatic Neoplasms / therapy*